Collegium Pharmaceutical, Inc. (COLL)

Collegium Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	707.01	631.45	566.77	463.93	276.87	310.02
Revenue Growth (YoY)	22.61%	11.41%	22.17%	67.56%	-10.69%	4.49%
Cost of Revenue	88.3	83.53	79.72	118.19	59.07	69.5
Gross Profit	618.71	547.92	487.05	345.74	217.8	240.52
Selling, General & Admin	247.16	182.98	150.71	172.19	118.96	113.83
Research & Development	-	-	-	3.98	9.45	9.77
Operating Expenses	454.37	348.29	296.47	307.64	195.59	184.28
Operating Income	164.33	199.63	190.58	38.11	22.21	56.23
Interest Expense	-82.3	-73.97	-83.34	-63.21	-21.01	-28.88
Interest & Investment Income	9.7	13.98	15.62	1.05	0.01	0.23
EBT Excluding Unusual Items	91.73	139.63	122.85	-24.06	1.2	27.58
Merger & Restructuring Charges	-37.25	-29.6	-15.12	-	-4.58	-
Asset Writedown	-	-	-	-4.79	-	-
Legal Settlements	-	-	-8.5	-	-	-
Other Unusual Items	-1.48	-11.47	-23.5	-	-	-
Pretax Income	53	98.57	75.73	-28.85	-3.37	27.58
Income Tax Expense	16.73	29.38	27.58	-3.85	-74.89	0.83
Net Income	36.27	69.19	48.16	-25	71.52	26.75
Net Income to Common	36.27	69.19	48.16	-25	71.52	26.75
Net Income Growth	-63.69%	43.68%	-	-	167.33%	-
Shares Outstanding (Basic)	32	32	34	34	35	34
Shares Outstanding (Diluted)	40	40	42	34	41	35
Shares Change (YoY)	-11.15%	-3.26%	23.53%	-17.58%	16.77%	5.07%
EPS (Basic)	1.13	2.14	1.43	-0.74	2.05	0.78
EPS (Diluted)	1.06	1.86	1.29	-0.74	1.86	0.76
EPS Growth	-56.39%	43.56%	-	-	144.25%	-
Free Cash Flow	201.81	203.33	274.29	122.61	101.61	88.4
Free Cash Flow Per Share	5.07	5.03	6.56	3.62	2.48	2.52
Gross Margin	87.51%	86.77%	85.93%	74.52%	78.66%	77.58%
Operating Margin	23.24%	31.61%	33.63%	8.21%	8.02%	18.14%
Profit Margin	5.13%	10.96%	8.50%	-5.39%	25.83%	8.63%
Free Cash Flow Margin	28.54%	32.20%	48.39%	26.43%	36.70%	28.51%
EBITDA	375.77	368.79	339.83	172.26	91.12	117.78
EBITDA Margin	53.15%	58.40%	59.96%	37.13%	32.91%	37.99%
D&A For EBITDA	211.43	169.16	149.26	134.15	68.92	61.55
EBIT	164.33	199.63	190.58	38.11	22.21	56.23
EBIT Margin	23.24%	31.61%	33.63%	8.21%	8.02%	18.14%
Effective Tax Rate	31.56%	29.80%	36.41%	-	-	3.01%
Advertising Expenses	-	10.66	7.41	11.74	4.19	5.37

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q